Matrix Laboratories, wholly owned subsidiary of Mylan Inc., has received clearance from World Health Organization (WHO) for its Unit No 8 located at Vizianagaram District in India. Earlier, this unit was notified concerns by the World Health Organization (WHO) Prequalification of Medicines Programme.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; operates the world's third largest active pharmaceutical ingredient manufacturer; and runs a specialty business focused on respiratory and allergy therapies.